PubMed Health⌕ Search

Biomedical subjects

M C Nicolson

Publications and source records attributed to M C Nicolson.

20 records · Page 2Linked to original sources

The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.

Three L1210 murine leukemia variants resistant to cisplatin, tetraplatin or carboplatin were compared with their sensitive parent line for differences in platinum accumulation, efflux and glutathione (GSH) content. All three resistant lines had reduced platinum accumulation compared with the sensitive line following exposure to each of the three drugs. There was no difference in the efflux of platinum between the sensitive and resistant lines indicating that reduced platinum accumulation was due to impaired uptake mechanisms. However, in cell survival experiments it was apparent that the resistant lines could tolerate higher intracellular platinum levels than the sensitive line. Intracellular GSH measurements revealed comparable levels in all but the L1210/carboplatin line which had a 2-fold elevation during the first 24 hours of culture. However, depletion of intracellular GSH with buthionin sulphoximine over a 72 hour period did not sensitize the resistant lines to the drugs. These studies have demonstrated that impaired platinum uptake is one of the mechanisms contributing to platinum drug resistance, while perturbations in GSH levels do not appear to play a role in these cell lines.

Animals↗

Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide, with a very poor survival rate. Therefore there is intense scrutiny to provide a better understanding of the molecular and cellular processes involved in this aggressive disease. The matrix metalloproteinases (MMPs) are a large family of extracellular matrix degrading enzymes believed to play a crucial role in tumor invasion and metastasis. MMP inhibitors are now under development as an adjuvant approach to surgical control of NSCLC. However, there is little data available on MMPs or their tissue inhibitors (TIMPs) in NSCLC. Expression of MMP1, MMP2, MMP9, TIMP1 and TIMP2 was assessed in 44 stage II NSCLC. All proteins were found to be expressed at high levels and significant co-expression was observed. These results suggest that a broad spectrum MMP inhibitor is worthy of evaluation as a therapeutic method of reducing tumor invasion and metastasis in stage II NSCLC.

Adult↗